highperformr logo

Byondis's Overview

Total employees274
HeadquartersNijmegen
Founded2012

Byondis is an independent, Dutch clinical-stage biopharmaceutical company committed to the development of innovative precision medicines targeting cancer and autoimmune diseases. Leveraging its proprietary linker-drug (LD) platform, GlycoConnect™, and its site-specific conjugation technology, Byondis creates next-generation antibody-drug conjugates (ADCs) and monoclonal antibodies. The company's pipeline features promising candidates, including its lead ADC [vic-]trastuzumab duocarmazine (SYD985), aimed at treating hard-to-treat cancers. Byondis focuses on translating novel scientific insights into therapies that address significant unmet medical needs and improve patient lives.

Where is Byondis's Headquarters?

HQ Function

The Nijmegen headquarters serves as the central hub for all of Byondis's core operations, including research and development, clinical trial management, cGMP manufacturing of biopharmaceuticals, and corporate functions.

Notable Features:

Located within the Noviotech Campus, the headquarters boasts state-of-the-art R&D laboratories, advanced biopharmaceutical manufacturing facilities compliant with cGMP standards, and modern office spaces designed to foster innovation and collaboration.

Work Culture:

Byondis fosters a work culture centered on scientific excellence, innovation, collaboration, and a strong patient-first mentality. Employees are encouraged to be agile, proactive, and contribute to a shared mission of developing life-changing treatments.

HQ Significance:

The headquarters is strategically vital, concentrating Byondis's scientific expertise, technological platforms, and manufacturing capabilities, enabling the seamless progression of drug candidates from discovery through clinical development and towards potential commercialization.

Values Reflected in HQ: The design and operation of the headquarters reflect Byondis's core values of innovation, quality, scientific rigor, and dedication to improving patient health through advanced biopharmaceutical solutions.

Location:

While its core R&D and manufacturing are centralized in Nijmegen, The Netherlands, Byondis has a global operational footprint. This is primarily driven by its international clinical trials conducted across Europe, North America, and other regions. The company's U.S. office in San Diego, CA, further supports its global activities, particularly in clinical development and regulatory interactions. Byondis collaborates with international research institutions, contract research organizations (CROs), and partners to advance its pipeline worldwide.

Street Address:

Microweg 22

City:

Nijmegen

State/Province:

Gelderland

Country:

The Netherlands

Byondis's Global Presence

San Diego, CA, USA

Address: Specific address not publicly listed; functions as a strategic presence.

To strengthen Byondis's operational capabilities and strategic partnerships in the key U.S. market, enhancing the global reach of its clinical programs and research initiatives.

Buying Intent Signals for Byondis

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Byondis

As of April 2025, Byondis' leadership includes:

Marco Timmers, Ph.D. - Chief Executive Officer
Wim Dokter, Ph.D. - Chief Scientific Officer
Marcel van der Sluis, M.Sc. - Chief Operations Officer
Corine van den Hout-Veeneman, M.Sc. - Chief Financial Officer
Mark Gitzinger, Ph.D., MBA - Chief Business Officer
Jan Schellens, M.D., Ph.D. - Chief Medical Officer

Investors of Byondis

Byondis has been backed by several prominent investors over the years, including:

Synthon International Holding B.V.

Executive New Hires/Exits in the Last 12 Months

Hire3
Exits1

Over the past year, Byondis has experienced key leadership transitions, including the appointment of Marco Timmers as permanent CEO, and strengthening its executive team with new appointments for Chief Business Officer and Chief Medical Officer to guide its strategic growth and pipeline advancement.

Departures

Paul Peter Tak, M.D., Ph.D., FMedSci, Paul Peter Tak stepped down as Chief Executive Officer after leading the company's spin-out and initial growth phase.

New Appointments:

Jan Schellens, M.D., Ph.D., Jan Schellens, an experienced oncologist and clinical researcher, joined Byondis as Chief Medical Officer.
Marco Timmers, Ph.D., Following a period as interim CEO, Marco Timmers was confirmed as the permanent Chief Executive Officer, bringing continuity from his prior role as CSO.
Mark Gitzinger, Ph.D., MBA, Mark Gitzinger was appointed Chief Business Officer, bringing extensive experience in biopharma business development and strategy.

Technology (Tech Stack) used by Byondis

Discover the tools Byondis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Byondis Email Formats and Examples

Byondis likely utilizes a common professional email format for its employees. Based on industry standards for companies of its size and nature, the most probable format is [firstinitial][lastname]@byondis.com or [first].[lastname]@byondis.com. Publicly available contact emails include generic addresses like info@byondis.com.

[first].[last]@byondis.com

Format

marco.timmers@byondis.com

Example

75%

Success rate

News and media

Byondis.comApril 22, 2024

Byondis Presents Preclinical Data on its CD123xCD3 Bispecific Antibody BYBA-029 Demonstrating Potent Anti-Tumor Activity in AML Models at AACR 2024

Byondis shared promising preclinical results for its bispecific antibody BYBA-029 at the AACR Annual Meeting 2024. The data indicated significant anti-tumor effects in acute myeloid leukemia (AML) models, highlighting its potential as a novel therapeutic agent for AML....more

Byondis.comDecember 7, 2023

Byondis Presents Positive Phase I Data on its CTLA-4 Targeting Antibody-Drug Conjugate BYON4228 in Solid Tumors at ESMO IO 2023

Byondis announced encouraging Phase I trial data for its ADC, BYON4228, which targets CTLA-4 in patients with various solid tumors. Presented at the ESMO Immuno-Oncology Congress 2023, the findings showed good tolerability and early signals of anti-tumor activity....more

Byondis.comSeptember 5, 2023

Byondis Appoints Marco Timmers as Chief Executive Officer and Mark Gitzinger as Chief Business Officer

Byondis announced the appointment of Marco Timmers, Ph.D., as its new Chief Executive Officer and Mark Gitzinger, Ph.D., MBA, as its new Chief Business Officer, strengthening its leadership team....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Byondis, are just a search away.